Conditions of employment:

• Eligible to work in U.S. (U.S. citizenship or work permit/authorization)

Why us

• Be part of a team pioneering cutting-edge research at the forefront of precision medicine
• Collaborate with a dynamic and innovative team of scientists in a fast-paced biotech environment
• Competitive benefits package

If you believe you are a strong fit for this position, please apply today!

To Apply: Please send your CV and Cover Letter to E-Mail schreiben. Please specify the position you are applying for and use the ""SCI-MET" " identifier in your cover letter and email subject line.

About the job

We are seeking highly motivated candidates to join our R&D team in San Diego, where you will work at the bench to develop cutting-edge multi-omics technologies aimed at identifying novel long non-coding RNAs (lncRNAs) and exploring their therapeutic potential. The ideal candidate needs a strong background in molecular and RNA biology with experience designing, performing and analyzing a wide array of cell & molecular biology assays in metabolic disease models.

At HAYA, you will be part of a highly collaborative, cross-functional team, applying your expertise in RNA and molecular biology to design and execute in vitro experiments for the identification of novel targets in metabolic diseases and assess their therapeutic potential in pre-clinical settings. As an integral early member, you will also develop high-throughput methodologies to test pioneering hypotheses, driving novel platform and therapeutic applications.

We are looking for creative, scientifically bold, independent, and goal-oriented scientists. Strong communication skills, a willingness to learn, and the ability to collaborate in a fast-paced entrepreneurial environment are essential.

Primary Responsibilities:

• Design and optimize in vitro models and assays for metabolic disease research
• Apply scientific knowledge, critical thinking, and creativity to design and execute experiments for the identification of novel lncRNA-targeting therapies in diverse pathological contexts
• Evaluation of the therapeutic potential and efficacy of novel targets using in vitro or pre-clinical models of metabolic disease
• Strategically triage ideas and translate new findings into actionable company assets, aiming for rapid proof-of-concept
• Develop and apply novel high-throughput methodologies to analyze nucleic acid expression, protein-DNA/RNA interactions, and epigenetic conformations
• Attend scientific conferences and foster relationships with key opinion leaders
• Generate, interpret, and present data to the R&D teams and senior managers
• Maintain an up-to-date electronic notebook record of performed studies

Qualifications:

The ideal candidate for this position needs:

• Ph.D. in metabolic diseases, RNA biology, or related field
• Expertise in metabolic disease models and assays, both in vitro and in vivo
• Strong background in RNA biology, molecular biology, epigenomic and gene transcription regulation
• Experience in designing, performing and analyzing a wide array of molecular biology assays including nucleic acid extraction from isolated cells and tissues, qRT-PCR, lentiviral production, CRISPR assays, and ASO transfection
• Proficient with NGS technologies such as ChIP-seq, RNA-seq, PRO-seq, and ATAC-seq
• Experience performing single cell RNA and ATAC in in vivo and in vitro models of metabolic diseases
• Proven track-record of scientific excellence as evidenced by a strong publication and/or patent record
• Bioinformatic skills for the analysis and interpretation of NGS assays are a plus
• Industry or post-doctoral experience in metabolic disease is a plus

HAYA Therapeutics is a precision RNA-based therapeutics company that discovers and develops innovative genomic medicines for the treatment of fibrosis and other serious health conditions associated with aging. The company’s discovery engine focuses on long non-coding RNAs (lncRNAs) within the “dark matter” of the human genome -- key tissue and cell-specific drivers of multiple disease processes including fibrosis -- to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments.

Headquartered in Lausanne, Switzerland with laboratory facilities in San Diego, USA, HAYA is a rapidly growing company led by a world-class team and supported by a strong investor consortium.